Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

Podobne knjige/članki

• Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
  od: Ke, E-E, et al.
  Izdano: (2016)
• Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
  od: Green, John A.
  Izdano: (2018)
• First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
  od: Park, Keunchil, et al.
  Izdano: (2019)
• Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study
  od: Park, Keunchil
  Izdano: (2016)
• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
  od: Greenhalgh, Janette, et al.
  Izdano: (2021)